The general plus of our P-tripeptides is that they probe different segments of the human proteome and might be taken advantage of to design pharmacological inhibitors of SMYD3 oncogenic PPIs as a means to alter the composition of multiprotein complexes involved in cancer hallmarks. The gene discussed is SMYD3; the disease is cancer.